Company intelligence / Profile preview

Bioiberica

Ownership: Private
Employees: ~292
Development stage: Commercial

Overview

Bioiberica is a global leader in heparin API production, which is used as an anticoagulant to save approximately 100 million lives annually. The company has expanded to develop over 100 products for human, animal, and plant health.

Therapeutic areas: CardiovascularRheumatology
Modalities: Biologically-derived moleculesHeparin APIChondroitin SulfateGlucosamineHyaluronic AcidNative CollagenHydrolysed ProteinsNucleotidesAmino AcidsCharacterised Peptides
Industry: Chemicals & Materials

Drug pipeline

1 asset

heparin

Commercial

Indications: deep vein thrombosis (DVT), pulmonary embolism / pulmonary thromboembolism (PE), systemic arterial embolism (SAE), peripheral arterial embolism (PAE), venous thromboembolism (VTE)

Partnerships

Works with over 30 public and private research centers in more than 10 countries

Beyond the preview

Go deeper on Bioiberica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioiberica.

Explore the full profile